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Background: α-Synuclein is the major component of filamentous inclusions that constitute the defining
characteristic of Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy, so-called
α-synucleinopathies. Recent studies revealed that intracerebral injection of recombinant α-synuclein fibrils into
wild-type mouse brains induced prion-like propagation of hyperphosphorylated α-synuclein pathology. However,
the propagation mechanisms of α-synuclein have not been fully elucidated.
Results: In this study, in order to establish where and how α-synuclein pathology propagates, we injected recombinant
mouse α-synuclein fibrils into three different brain areas (substantia nigra, striatum, and entorhinal cortex) of wild-type
mice and compared the resulting distributions of α-synuclein pathology at 1 month after injection. Distinct patterns of
pathology were observed in mice injected at the different sites. Within one month after injection, the pathology had
spread to neurons in areas far from the injection sites, especially areas with direct neural connections to the injection
sites. Surprisingly, phosphorylated tau and TDP-43 pathologies were also observed in mice injected with α-synuclein
fibrils into striatum and entorhinal cortex at one month after injection. Phosphorylated tau and TDP-43 were
accumulated in dot-like inclusions, but these were rarely colocalized with α-synuclein pathology. It seems that
accumulation of α-synuclein has a synergistic effect on tau and TDP-43 aggregation. Additionally, intracerebral injection
with sarkosyl-insoluble fraction prepared from wild-type mice injected synthetic α-synuclein fibrils can also induce
phosphorylated α-synuclein pathology in wild-type mice.
Conclusions: Our data indicate that α-synuclein aggregation spread by prion-like mechanisms through neural networks
in mouse brains.
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Parkinson’s disease (PD) and dementia with Lewy bodies
(DLB) are progressive neurodegenerative diseases charac-
terized by appearance of Lewy bodies (LBs) and Lewy
neurites (LNs) [1]. α-Synuclein (αsyn) is the major compo-
nent of LBs and LNs, and is deposited in a hyperpho-
sphorylated form in β-sheet-rich amyloid fibrils [2-5]. Five
missense mutations in the αsyn gene and occurrence of
gene multiplication have been identified in the familial
forms of PD and DLB [6-13]. Moreover, it was reported
that the mutations affect amyloid fibril formation in vitro,* Correspondence: hasegawa-ms@igakuken.or.jp
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article, unless otherwise stated.either accelerating fibril formation [14-16] or resulting in
formation of fibrils that are more fragile and easy to
propagate than wild-type (WT) fibrils [17]. These results
clearly indicate that abnormalities of αsyn can induce PD
and DLB. Distribution of αsyn pathology in brains with
sporadic PD occurs from olfactory bulb and/or brainstem,
and spreads to other brain regions concomitantly with
progression of disease symptoms [18,19]. Thus, spread of
αsyn pathology in the brain can be regarded as the under-
lying mechanism of progression of these diseases. Recently
intracerebral injection of synthetic αsyn fibrils and/or
insoluble αsyn from diseased brain was shown to induce
αsyn pathology that propagated throughout the brain in a
prion-like manner in WT mouse [20,21], αsyn transgenic
mouse [22-24] and monkey [25]. However, the mecha-
nisms through which exogenous abnormal fibrils entered Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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to other neurons remain unknown.
To investigate where αsyn pathologies develop and how
they propagate, we injected recombinant αsyn fibrils into
substantia nigra, striatum, or entorhinal cortex of WT mice,
and compared the spreading patterns and distribution of
phosphorylated αsyn pathologies at 1 month after intrace-
rebral injections. Our results clearly suggest that propaga-
tion of pathological αsyn occurred along neural circuits and
involved trans-synaptic transport. We also showed that
αsyn pathology induced tau and TDP-43 accumulation in
WT mice, similar to that seen in DLB brains. This mouse
model should be useful for elucidating mechanisms of dis-
ease progression of synucleinopathy and also for develop-
ment of novel disease-modifying drugs.
Materials and methods
Antibodies
Antibodies used in this study are summarized in Additional
file 1: Table S1. 1175 polyclonal antibody was raised against
an αsyn peptide phosphorylated at serine 129 [21,26]. Anti-
phosphorylated αsyn mouse monoclonal antibody, #64 [5]
and anti-human αsyn specific mouse monoclonal antibody,
LB509 [27] were kindly provided from Dr. Iwatsubo.Figure 1 Distribution of phosphorylated αsyn pathology in αsyn fibri
induced αsyn pathology mainly in SN (3.08 mm posterior to bregma), amy
anterior to bregma). (B) Injection into Str induced severe αsyn pathology t
amygdala (1.58 mm posterior to bregma), SN (2.70 mm posterior to bregm
pathology that was concentrated in EC (3.52 mm posterior to bregma), den
bregma), fimbria (1.94 mm posterior to bregma), and septal nucleus (0.02 m
injection site and psyn pathology, respectively.Rabbit polyclonal pS396 antibody (Calbiochem) is specific
for phosphorylated tau at serine 396; biotin-AT8 (Thermo
Scientific) is specific for phosphorylated tau at serine 202/
threonine 205; anti-mouse αsyn rabbit monoclonal anti-
body (Cell Signaling Technology) is specific for mouse
αsyn. Rabbit polyclonal pTDP-43 antibody is specific for
phosphorylated at serine 409/410 [28].
Preparation of recombinant αsyn monomer and fibrils
Mouse αsyn cDNA in bacterial expression plasmid pRK172
was used. αSyn were expressed in Escherichia coli BL21
(DE3) cells and purified using boiling, Q-sepharose ion ex-
change chromatography and ammonium sulfate precipita-
tion. Purified αsyn protein was dialyzed against 30 mM
Tris–HCl, pH 7.5, and cleared using ultracentrifugation at
113,000 g for 20 min. Protein concentration was deter-
mined by reverse phase HPLC. Proteins were loaded on an
Aquapore RP-300 column (PerkinElmer Brownlee) equili-
brated in 0.09% trifluoroacetic acid with linear gradient of
acetonitrile 0 to 50% at a flow rate of 1 ml/min [21]. Puri-
fied mouse αsyn monomer (7 mg/ml) in 30 mM Tris–HCl,
pH 7.5, containing 0.1% NaN3 was incubated at 37°C in
a shaking incubator at 200 rpm for 72 h. αSyn fibrils
were pelleted by spinning at 113,000 g for 20 min andl-injected mice at 1 month after injection. (A) Injection into SN
gdala (1.58 mm posterior to bregma) and stria terminalis (0.02 mm
hroughout the brain, including Str (0.26 mm anterior to bregma),
a) and a wide range of cortex. (C) Injection into EC induced αsyn
tate gyrus (3.52 mm posterior to bregma), CA3 (3.52 mm posterior to
m anterior to bregma). Blue-dashed box and red dots indicate the
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ultrasonic homogenizer (VP-5S, TAITEC) before use.
To determine the concentration, fibrils were dissolved
in 8 M guanidine hydrochloride and analyzed by RP-
HPLC as described above.Mice
C57BL/6 J mice, used as WT mice, were purchased from
CLEA Japan, Inc. αSyn (SNCA) knockout mice [29] were
purchased from the Jackson Laboratory.Stereotaxic surgery
Four- to six-month-old mice anesthetized with 50 mg/
kg pentobarbital sodium were unilaterally injected with
10 μg of recombinant mouse αsyn fibrils into substantia
nigra (SN, n = 6) (A-P: −3.0 mm; M-L: −1.3 mm; D-V: −4.7
mm from the bregma and dura) [21], striatum (Str, n = 6)
(A-P: 0.2 mm; M-L: −2.0 mm; D-V: −2.6 mm) [20], or en-
torhinal cortex (EC, n = 6) (A-P: −3.1 mm; M-L: −4.0 mm;
D-V: −2.7 mm). Mice were anesthetized with isoflurane
and killed by decapitation. For immunohistochemistry
(IHC, n = 3), brains were fixed in 10% formalin neutral
buffer solution (Wako). For biochemical analysis (n = 3),
brains were snap-frozen on dry ice and stored at −80°C.
All experimental protocols were approved by the AnimalFigure 2 Staining of WT mouse brains injected with αsyn fibrils at 1 m
in mice injected into SN. (B) Psyn pathology in mice injected into Str. (C) P
amygdala, ST: stria terminalis, Str: striatum, Ctx: cortex, EC: entorhinal cortexCare and Use Committee of the Tokyo Metropolitan Insti-
tute of Medical Science.
Peripheral injection of αsyn
For intraperitoneal injection, 2-month-old C57BL/6 J mice
were injected intraperitoneally with 100 μg of mouse αsyn
monomer or fibrils. At 6 months after injection, the path-
ology of mouse brains in both groups (n = 3 each) was
tested by immunohistochemistry (IHC). For oral adminis-
tration, 2- or 3-month-old C57BL/6 J mice were orally ad-
ministrated with 400 μg of human αsyn monomer, human
αsyn fibrils, mouse αsyn monomer or mouse αsyn fibrils
every two weeks for 4 times. At 12 months post final ad-
ministration, pathology in mouse brains (n = 3 each) was
analyzed by IHC.
Immunohistochemistry
Fixed brains were cut on a vibratome (Leica) at 50 μm
thickness. For high-sensitivity detection, mouse brain sec-
tions were treated with formic acid for 30 min, washed,
and boiled at 100°C for 30 min. The sections were then
incubated with 0.5% H2O2 in methanol to inactivate en-
dogenous peroxidases, blocked with 10% calf serum in PBS,
and immunostained with appropriate antibodies. After in-
cubation with the biotinylated-secondary antibody (Vector),
labeling was detected using the ABC staining kit (Vector).onth after injection by using 1175 antibody. (A) Psyn pathology
syn pathology in mice injected into EC. SN: substantia nigra, Amy:
, DG: dentate gyrus. Scale bar represents 50 μm.
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For double-label immunofluorescence to detect phos-
phorylated αsyn and tau, brain sections were incubated
overnight at 4°C in a cocktail of #64 antibody and anti-
pS396 antibody. The sections were washed and in-
cubated in a cocktail of Alexa568-conjugated goat anti
mouse IgG (Molecular Probes) and Alexa488-conjugated
goat anti rabbit IgG (Molecular Probes). After further
washing, sections were stained with TOPRO-3, cover-
slipped with Vectashield (Vector) and observed with aFigure 3 Induction of phosphorylated tau inclusions in WT mice injec
tau was not accumulated in mice injected into SN, based on staining with
mice injected into Str by using anti-pS396 antibody (B) and AT8 (C) (D-E).
using anti-pS396 antibody (D) and AT8 (E). SN: substantia nigra, Amy: amyg
DG: dentate gyrus. Scale bar represents 50 μm.laser-scanning confocal fluorescence microscope (LSM5
PASCAL; Carl Zeiss).
Biochemical analysis
Biochemical analysis of mouse brains (n = 3 per group)
was conducted as described previously [21]. Briefly,
brains were homogenized in 20 volumes (w/v) of buffer
A (10 mM Tris–HCl, pH 7.4, 0.8 M NaCl, 1 mM EGTA
and 10% sucrose), then spun at 100,000 g for 30 min at
4°C, and the supernatant was retained as buffer-solubleted with αsyn fibrils at 1 month after injection. (A) Phosphorylated
anti-pS396 antibody. (B-C) Dot-like tau inclusions were observed in
Dot-like tau inclusions were also detected in mice injected into EC by
dala, ST: stria terminalis, Str: striatum, Ctx: cortex, EC: entorhinal cortex,
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buffer A containing 1% Triton X-100 and incubated for
30 min at 37°C. After centrifugation at 100,000 g, the
Triton-insoluble pellet was further homogenized in buf-
fer A containing 1% sarkosyl and incubated at 37°C for
30 min. Samples were spun at 100,000 g for 30 min. The
sarkosyl-pellet was sonicated in 30 mM Tris–HCl, pH
7.4, and used for immunoblotting as sarkosyl-insoluble
fraction. The samples were subjected to SDS-PAGE and
proteins were electrotransferred onto a polyvinylidene
difluoride membrane, probed with appropriate anti-
bodies and detected as described previously [21].
Behavioral tests
For behavioral tests, C57BL/6 J male mice were used.
Mouse αsyn fibrils (10 μg) were injected into SN (n = 10),
Str (n = 15), or EC (n = 14) of 3-month-old mice, and the
same amount of mouse αsyn monomer was injected into
SN (n = 9), Str (n = 8), or EC (n = 8) of control mice. At 3
months after injection, motor and cognitive activities were
evaluated as described below.
Rotarod test
Motor coordination and balance were measured in terms
of performance on the rotarod. Mice were placed on 3-cmFigure 4 Induction of phosphorylated TDP-43-positive structures in W
(A) Phosphorylated TDP-43 was not accumulated in mice injected into SN,
inclusions were observed in mice injected into Str. (C) Dot-like TDP-43 inclu
Amy: amygdala, ST: stria terminalis, Str: striatum, Ctx: cortex, EC: entorhinaldiameter rods and the speed of the rotation was in-
creased from 0 to 40 rpm over 5 min. Latency to fall
was recorded. Each mouse was tested three times and
the average was used. Statistical analyses were per-
formed using Student’s t-test.Wire hang test
Neuromuscular abnormalities were tested with the wire
hang test. The mouse was placed on a wire cage lid, which
was waved gently so that the mouse gripped the wire and
then inverted. Latency to fall was recorded with a 300-sec
cut-off time. The test was conducted three times and stat-
istical analyses were performed using Student’s t-test.Y-maze test
The Y-maze apparatus (Muromachi kikai) consisted of
three arms (40 cm × 3 cm) made of grey plastic joined in
the middle to form a Y shape. Mice were placed into one
of the arms of the maze and allowed to freely explore
the three arms for an 8-min session. Alternation be-
tween arms was recorded. The Y-maze test was con-
ducted twice. Statistical analyses were performed using
Student’s t-test.T mice injected with αsyn fibrils at 1 month after injection.
based on staining with anti-pS409/410 antibody. (B) Dot-like TDP-43
sions were also detected in mice injected into EC. SN: substantia nigra,
cortex, DG: dentate gyrus. Scale bar represents 50 μm.
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Recombinant human αsyn fibrils (10 μg) were injected
into SN of 4-month-old WT mice (n = 4). At 9 months
after injection, sarkosyl-insoluble pellets were prepared
from the whole brains as described above, collected in one
tube, and stored at −80°C until use. Sarkosyl-insoluble pel-
lets were suspended in 100 μl PBS and sonicated for 30
seconds (TAITEC, VP-5S), and 5-μl aliquots were injected
into Str of 4-month-old WT mice (n = 10). At 3 months
post injection, pathology was analyzed by IHC.
Results
We investigated the spread of αsyn pathology in brains
of mice after unilateral injection of recombinant mouse
αsyn fibrils into SN, Str, or EC. We confirmed the purity
of recombinant αsyn monomer and fibrils used in this
study; they didn’t contain any contaminants (Additional
file 1: Figure S1). Using highly sensitive immunohisto-
chemistry (IHC) with anti-phosphorylated αsyn (psyn)
antibody 1175, we evaluated αsyn pathology in the brains
at 1 month after injection. The distribution of αsyn path-
ology observed in these mice is illustrated in Figure 1. In
mice injected into SN (Figure 1A), abnormal psyn path-
ology was restricted mainly to SN (3.08 mm posterior
to bregma), amygdala (1.58 mm posterior to bregma),
and stria terminalis (0.02 mm anterior to bregma) of theFigure 5 Dot-like ptau-positive structures showed little colocalization
fibrils into EC at 1 month after injection. Brain sections were double-lab
green). Scale bar represents 50 μm.hemisphere on the injection side. In these mice, psyn was
accumulated in neurites and soma (Figure 2A). In mice
injected into Str, psyn pathology was widely distributed
bilaterally throughout the brain, including Str (0.26 mm
anterior to bregma), amygdala (1.58 mm posterior to
bregma), SN (2.70 mm posterior to bregma) and cortex
(Figure 1B). Psyn pathology was accumulated mainly in
neurites, and partly in soma (Figure 2B). Injection of αsyn
fibrils into EC induced severe psyn pathology in EC (3.52
mm posterior to bregma), dentate gyrus (3.52 mm poster-
ior to bregma), hippocampal CA3 region (1.94 and 3.52
mm posterior to bregma), fimbria (1.94 mm posterior to
bregma), and septal nuclei (0.02 mm anterior to bregma)
on the injection side, as well as moderate psyn pathology
in hippocampus on the contralateral side (Figure 1C). Psyn
pathology was mainly observed in neurites and perinuclear
regions (Figure 2C). No such psyn accumulation was de-
tected in αsyn KO mice injected with αsyn fibrils into Str
(Additional file 1: Figure S2A). Thus, there are major dif-
ferences among these mice in the development and spread
of αsyn pathologies, demonstrating that the propagation
pattern depends upon the injection site.
To investigate whether other pathologies are also in-
duced by the injection of αsyn fibrils, we performed IHC
analysis using anti-tau, anti-TDP and anti-Aβ antibodies.
No tau pathology was observed in mice injected into SNwith psyn pathology in hippocampus of mice injected with αsyn
eled with anti-psyn antibody (#64, red) and anti-ptau antibody (pS396,
Figure 6 Intracerebral injections with αsyn fibrils induced
accumulation of endogenous αsyn and tau in WT mice. At 3
months after injection, sarkosyl-insoluble fractions were prepared
from the right and left brains and analyzed by immunoblotting
with #64, anti-mouse syn and anti-pS396 antibodies. Band patterns
of insoluble psyn were identical to that of DLB brain. Insoluble ptau
was also accumulated in mouse brains showing abundant accumulation
of αsyn. L: left brain, R: right brain.
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Str, pS396-positive dot-like structures were observed in
Str, amygdala, and cortex (Figure 3B). Anti-phosphorylated
tau (ptau) antibody AT8 also stained these structures in
Str (Figure 3C). Similar ptau-positive dot-like structures
were also observed with anti-pS396 antibody in EC,
dentate gyrus and CA3 of the mice injected into EC,
and were most frequent in CA3 (Figure 3D). Similar
staining was observed in CA3 and dentate gyrus with
AT8 antibody (Figure 3E). Furthermore, phosphorylated
TDP-43 was also accumulated in mice injected into Str
and EC (Figure 4B,C), although it was not detected in
mice injected into SN (Figure 4A) at 1 month after in-
jection. Aβ pathology was never observed in αsyn fibril-
injected mice, regardless of injection site (Additional file 1:
Figure S3). The tau and TDP-43 pathologies differed from
psyn pathology in both shape and localization; most psyn
pathologies were not colocalized with ptau-positive struc-
tures and the overlap was small (Figure 5).
To confirm the accumulation of these proteins and to
analyze them biochemically, we next investigated sarkosyl-
insoluble fractions of these mice brains at 3 months after
injection into SN, Str or EC (Figure 6). Sarkosyl-insoluble
psyn was detected in both the right and left hemispheres
of all these mice, though it was more abundant on the in-
jection side. The accumulation was most abundant on the
injection side (right brain) in mice injected into Str, and
less abundant on the uninjected side in mice injected into
SN or EC. The banding patterns of sarkosyl-insoluble psyn
were identical among these mice, regardless of the injec-
tion site, and were indistinguishable from that of DLB
brain (Figure 6 upper). Anti-mouse αsyn antibody showed
the same banding pattern as psyn antibody (Figure 6
middle). The 15, 22, 30 and 35 kDa bands correspond to
monomer, monoubiquitinated αsyn, dimer and ubiquiti-
nated dimer, respectively. Moreover, sarkosyl-insoluble
ptau was detected in the right hemisphere of mice injected
into Str, where the most abundant tau inclusions were
observed (Figure 6 lower). On the other hand, αsyn and
tau accumulations were not observed in αsyn KO mice
injected with fibrils into Str (Additional file 1: Figure S4).
These results indicate that inoculation of αsyn fibrils con-
verted mouse αsyn at the injection sites to an abnormal
form, that this change propagated from the injection site
to the contralateral side of the brain, and that inoculation
into Str also induced tau pathology.
Next, we analyzed motor and cognitive functions of these
mice at 3 months after injection (Figure 7). Mice injected
with αsyn fibrils into SN and Str showed poorer perform-
ance on the rotarod test compared with control mice
injected with soluble αsyn (Figure 7A). Mice injected into
SN also performed poorly on the wire hang test (Figure 7B).
Cognitive dysfunction was not observed in any group in
the Y-maze test (Figure 7C).Finally, to examine whether insoluble αsyn induced in
WT mice shows prion-like propagation behavior, we
assessed the transmissibility of insoluble αsyn prepared
from fibril-injected WT mouse brains. In brief, sarkosyl-
insoluble αsyn was prepared from WT mouse brains
injected with recombinant αsyn fibrils and was injected
into Str of other WT mouse brains (Figure 8A, B). Induc-
tion and propagation of psyn pathology were examined by
IHC. At 3 months after injection, psyn pathology was ob-
served in Str (0.26 mm anterior to bregma) and had also
propagated to amygdala (1.46 mm posterior to bregma)
and SN (3.08 mm posterior to bregma) (Figure 8C). The
distribution of psyn pathology is illustrated in Figure 8D.
These data clearly showed that insoluble αsyn derived
from WT mice injected with αsyn fibrils exhibits prion-
like transmissibility.
Figure 7 Fibril-injected mice showed motor dysfunctions compared to monomer-injected mice at 3 months after injection. (A) Rotarod
test. Mice injected into SN and Str showed lower performance in the rotarod test. (B) Wire hang test. (C) Y-maze test. All error bars indicates
mean ± S. E. M. *p < 0.01, **p < 0.05. M: αsyn monomer-injected, F: αsyn fibril-injected.
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Luk et al. and we have established that insoluble αsyn
shows prion-like propagation behavior in WT mouse brain
[20,21], but the mechanism of spreading remains poorly
understood. In this study, we investigated the spread and
distribution pattern of psyn pathology in mouse brain
injected with recombinant αsyn fibrils into three different
brain regions: SN, Str, and EC. We assessed the distribution
at 1 month post injection by using highly sensitive IHC.
Pretreatment of brain sections with formic acid and heat
enabled detection of psyn pathology at only 1 month after
injection. When αsyn fibrils were injected into SN, psyn
pathology only appeared in the central nucleus of amygdala
and stria terminalis, which are located far from SN,
while there was no detectable psyn pathology around SN
(Figure 1A). Amygdala is connected with SN [30], and stria
terminalis serves as a major output pathway of the central
nucleus of amygdala. These findings strongly indicate that
spreading of psyn pathology does not occur by simple dif-
fusion or nonspecific transport. In the case of injection into
Str, psyn pathology was observed in amygdala, SN and awide range of cortices (Figure 1B). Str has direct projection
to SN and amygdala [31], and many parts of the neocortex
innervate the Str [32]. Injection into EC induced pathology
in EC, dentate gyrus, hippocampal CA3, fimbria and septal
nucleus (Figure 1C). Dentate gyrus receives projection
from EC via the perforant pathway, and septal nucleus
and fimbria have direct connections with hippocampus.
Therefore, the data strongly suggest that propagation of
pathological αsyn occurs via axonal transport and a trans-
synaptic pathway, in accordance with reports that αsyn fi-
brils can be internalized by neurons and transferred from
axons to second-order neurons in culture [33] and in ani-
mal models [34,35]. In patients with sporadic PD, the distri-
bution of Lewy bodies and Lewy neurites seems to spread
retrogradely [18,36]. In the present study, focusing on Str
and SN, injection with αsyn fibrils into Str induced αsyn
pathology in SN at 1 month after injection (Figure 1B).
However, injection into SN did not induce pathology in Str
at that time (Figure 1A), and pathology only became appar-
ent in Str at 3 months after injection [21], indicating there
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Figure 8 Sequential transmission of insoluble αsyn. (A) Schematic diagrams of transmission experiments. Sarkosyl-insoluble fractions were
prepared from WT mouse brains injected with recombinant αsyn fibrils at 9 months post-injection and intracerebrally injected into 4-month-old
WT mice. At 3 months after injection, transmission of αsyn pathology was analyzed by IHC. (B) Immunoblot of sarkosyl-insoluble fractions from
WT mice at 9 months post-injection with #64 antibody and anti-msyn antibody. (C) Psyn pathology was observed mainly in Str, amygdala and SN
with 1175 antibody. Scale bar represents 50 μm. (D) Distribution of psyn pathology in WT mouse brains injected with sarkosyl-insoluble fractions.
Blue-dashed box and red dots indicate the injection site (Str) and psyn pathology, respectively.
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anterograde transport (Figure 1C). At least under our
experimental conditions, propagation of αsyn seems to
occur via both anterograde and retrograde transport pro-
cesses. Thus, the predominant direction of spread presum-
ably depends on cell types or brain areas. Similarly, tau isalso reported to propagate via a trans-synaptic pathway in
animal models [37,38]. Thus, axonal transport and trans-
synaptic transport appear to be common pathways of
propagation of intracellular aggregated proteins.
In addition, we found that tau and TDP-43 accumula-
tion also occurred in WT mice injected with αsyn fibrils
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and 4). The morphological patterns of tau and TDP-43
accumulation were apparently different from that of αsyn
pathology (Figures 2, 3 and 4) and there was little colocali-
zation (Figure 5), as in DLB brains [39,40] and a DLB
mouse model [41]. Recently, Guo et al. reported that there
are two strains of recombinant αsyn fibrils, strains A and
B, and the two strains differently affect tau inclusion
formation [42]. They reported that strain A (preformed fi-
brils) only infrequently induced tau inclusions and psyn
pathology showed little colocalization with tau inclusions,
whereas strain B (generated through repetitively seeded
fibrillization in vitro) efficiently induced tau inclusions that
were highly colocalized in neurons. The αsyn fibrils we
used in this study are similar to strain A, and in agreement
with their work [42], we also detected small amounts of
tau inclusions that showed little colocalization with αsyn
pathology. In addition, tau accumulation was not observed
in αsyn KO mice injected with αsyn fibrils by biochemical
analysis (Additional file 1: Figure S4) or IHC (Additional
file 1: Figure S2B). Thus, tau accumulation was induced by
αsyn accumulation, and this occurred through a synergistic
effect rather than a cross-seeding effect. The tau accumu-
lation might be caused by a secondary effect of αsyn accu-
mulation, such as dysfunction of cellular activity [43,44] or
abnormality in protein degradation machinery [45].
Biochemical analysis clearly showed that accumulated
αsyn was phosphorylated and ubiquitinated similarly to
that in DLB brain, regardless of injection site (Figure 6).
This indicates that injection with the same fibrils as
seeds induces αsyn aggregation in the same fashion, as is
the case with prion strains.
Furthermore, αsyn fibril-injected mice showed modest
motor abnormalities compared to the monomer-injected
mice at 3 months after injection (Figure 7). This strongly
suggests that propagation of psyn pathology induced
motor phenotypes, although we could not detect cognitive
dysfunction in the Y-maze test. It is possible that this is be-
cause we injected αsyn fibrils unilaterally, and the func-
tions of the contralateral side of brain might be well
maintained. In our previous study, we could not detect
any abnormalities in fibril-injected mice at 6 months after
injection [21]. The discrepancy may have arisen from dif-
ferences in the test conditions, because in the previous
study, we used female mice injected with human αsyn fi-
brils, whereas in this study we used male mice injected
with mouse αsyn. Mouse αsyn fibrils propagate more effi-
ciently in WT mice than do human fibrils [21], and we
think this was the main reason why we could detect motor
abnormalities in the present study.
We next examined if insoluble αsyn accumulated in
WT mice shows transmissibility. Our results demon-
strate that insoluble αsyn accumulated in WT mice can
induce αsyn pathology in other WT mice (Figure 8C, D),analogously to prion transmission. We also examined in-
traperitoneal injection or oral administration with αsyn
fibrils into WT mice (see Materials and methods), but
failed to detect any psyn pathology in the central ner-
vous system at 6 months or 14 months after injection,
respectively (data not shown).
Conclusions
Intracerebral injection with αsyn fibrils into WT mouse
brains enables to induce phosphorylated αsyn pathology
and the distribution of pathology depends on the injec-
tion sites. Furthermore, αsyn pathology has a synergistic
effect on tau and TDP-43 aggregation. We conclude
that αsyn fibrils have prion-like transmissibility and it
might spread via axonal and trans-synaptic transports
in mouse brains.
Additional file
Additional file 1: Table S1. Antibodies used in this study. Figure S1.
HPLC charts of recombinant mouse αsyn used in this study. Mouse syn
monomer showed only one peak that is derived from msyn monomer.
Mouse syn fibril gave two peaks at 0.14 min (guanidine HCl) and at 6.8
min (msyn fibril). Figure S2. αSyn and tau accumulation was never
observed in fibril-injected αsyn KO mice at 3 months after injection. (A)
No psyn-positive pathology was observed with 1175 antibody. (B) Tau
accumulation was not detected with pS396 antibody. Str: striatum, Amy:
amygdala, SN: substantia nigra, sensory ctx: sensory cortex. Scale represents
50 μm. Figure S3. Aβ accumulation was not observed in αsyn fibril-injected
WT mice at 1 month post injection. Sections were stained with anti-mouse
Aβ antibody. Mice injected into SN (A), Str (B), and EC (C). SN: substantia
nigra, Amy: amygdala, ST: stria terminalis, Str: striatum, Ctx: cortex, EC:
entorhinal cortex, DG: dentate gyrus. Scale represents 50 μm. Figure S4.
Biochemical analysis of αsyn KO mice injected with human αsyn fibrils. The
brain was divided into two parts at the longitudinal fissure of the cerebrum.
Sarkosyl-insoluble fractions were obtained from the right and left brains, and
analyzed by immunoblotting with #64, LB509 or anti-mouse αsyn antibodies.
Exogenous human αsyn fibrils were detected in sarkosyl-insoluble fractions
and were not phosphorylated at 0 and 7 days after injection. They were
subsequently degraded and disappeared within 30 days post injection.
Phosphorylated αsyn accumulation was never observed at 90 days after
injection.
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